Kyverna Therapeutics (KYTX) Debt Ratio (2025 - 2026)
Kyverna Therapeutics' (KYTX) quarterly Debt Ratio came in at 0.1 in Q1 2026, up 14.64% on a QoQ basis from 0.08 in Q4 2025.
Powered by 
Analysis
Kyverna Therapeutics (KYTX) Debt Ratio (2025 - 2026) Analysis & Trends
Kyverna Therapeutics (KYTX) has 2 years of Debt Ratio data on file, last reported at 0.1 in Q1 2026.
- Quarterly Debt Ratio changed N/A year-over-year to 0.1 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.1 (changed N/A YoY) and the FY2025 annual result came in at 0.08, changed N/A from the prior year.
- Debt Ratio rose to 0.1 in Q1 2026, from 0.08 in the prior quarter.
- In the past five years, Debt Ratio ranged from a high of 0.1 in Q1 2026 to a low of 0.08 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 0.05 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 0.05 |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 0.12 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 0.47 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 0.26 |
| 10 | Kyverna Therapeutics | 505.44 Mn | 505.44 Mn | - | 0.11 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 0.11 |
| Mar 31, 2026 | 0.10 |
| Dec 31, 2025 | 0.08 |